Fibrodysplasia Ossificans Progressiva Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
MONTREAL, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ:CMTA), a clinical-stage biopharmaceutical company innovating new treatments for people with ultra-rare bone disorders and other diseases, today announced the start of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 12, 2017 Category: Pharmaceuticals Source Type: clinical trials

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva
Condition: Fibrodysplasia Ossificans Progressiva Interventions: Drug: REGN2477; Drug: Matching placebo Sponsor: Regeneron Pharmaceuticals Not yet recruiting - verified June 2017 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 13, 2017 Category: Research Source Type: clinical trials